…for ovarian cancer continues to show promise. The SOLO-1 trial, for instance, illustrates that the PARP inhibitor olaparib can significantly improve progression-free survival for patients with an inherited BRCA mutation….
…BRCA genes — cancer cells are defective in one type of repair mechanism. But PARP fixes damaged DNA using a different mechanism. This means that PARP inhibitors, by blocking PARP,…
(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly…
…(also called hereditary non-polyposis colon cancer syndrome or HNPCC), Cowden syndrome, or BRCA1 mutations. People with these genetic disorders may consider having yearly testing for endometrial cancer with a pelvic…
…TILs, as well as BRCA 1 mutation carriers. BRCA 2 carriers were not observed to benefit from them. The study authors concluded, “that the extent of infiltration is prognostic, not…
…of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough therapy” is a drug to…
Inherited gene mutations, such as BRCA 1 and BRCA 2, can increase the risk of developing ovarian cancer as well as uterine (endometrial) cancer. Some of these mutations, which affect…
…targeted treatment pathway at the time of diagnosis. The ability to determine germline and somatic mutations in BRCA and other BRCA-like genes can determine the best use of treatment strategies…
…BRCA 1 or 2 positive and newly diagnosed with an advanced stage of high grade serous or endometroid ovarian cancer, primary peritoneal, or fallopian tube cancer. Before starting olaparib, patients…
…for patients. Dr. Adams initial project, Development of Combination Therapy with PARP-inhibitors and Immunomodulation for BRCA-1 Epithelial Ovarian Cancer, explored a combination of PARP-inhibitor and immunotherapy to target CTLA-4 antibodies…
…recommendations are published as “Recommendation Statements” and have formed the basis for clinical standards in medical practice. The USPSTF has launched a new initiative on Genetic Risk Assessment and BRCA Mutation…
…doctors encouraging their patients with a BRCA mutation to undergo bilateral salpingectomy as a preventative measure for ovarian cancer. Dr. Miller took it a step further. “Dianne Miller was an…
Get email updates about research news, action alerts, and ways to join the fight.
